The post-Rocephin period
Holubiak was product manager for Rocephin, the major Roche injectable antibiotic, when it was launched. He comes back to Roche as that key product is approaching patent expiration and the company's recent entries into the retail drug sector have run into post-approval problems. Zenner said that Holubiak was recruited "to lead our marketing and sales effort as we prepare for an unprecedented, intense period of product approvals and launches." As a management consultant specializing in managed care markets and local variations in markets, Holubiak was a convincing proponent of a broader definition for the business: health care, not just drugs
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth